Experienced in Hairy Cell Leukemia (HCL)

Dr. Catherine E. Lai

Hematology | Oncology
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in Hairy Cell Leukemia (HCL)
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Catherine Lai is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Lai is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Lai is currently accepting new patients.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
George Washington University
Residency
University of Illinois Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Hematology, 2016
Medical Oncology, 2015
Internal Medicine, 2011
Fellowships
National Cancer Institute
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104
Call: 215-615-5858

Additional Areas of Focus

Dr. Lai has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Myelofibrosis
Polycythemia Vera

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

Phase IB/II of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation
Phase IB/II of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation
Enrollment Status: Recruiting
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: CPX-351
Study Phase: Phase 1/Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: November 17, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Ibrutinib, Lenalidomide, Rituximab
Study Phase: Phase 1
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Azacitidine, Pembrolizumab, Venetoclax
Study Phase: Phase 2
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Enrollment Status: Terminated
Publish Date: August 01, 2024
Intervention Type: Diagnostic test
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: October 30, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Nick C. Leasure
Hematology Oncology | Hematology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Nick C. Leasure
Hematology Oncology | Hematology | Oncology

Reading Hospital

420 S 5th Ave, Outpatient Services, 
West Reading, PA 
 (47.9 miles away)
484-628-8103
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nick Leasure is a Hematologist Oncology specialist and a Hematologist in West Reading, Pennsylvania. Dr. Leasure is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Hairy Cell Leukemia (HCL), and Reticuloendotheliosis.

Distinguished in Hairy Cell Leukemia (HCL)
Dr. John D. Sprandio
Hematology Oncology | Hematology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. John D. Sprandio
Hematology Oncology | Hematology | Oncology

Consultants In Medical Oncology And Hematology PC

30 Lawrence Rd, Suite 201, 
Broomall, PA 
 (8.0 miles away)
610-492-5900
Languages Spoken:
English
See accepted insurances

John Sprandio is a Hematologist Oncology specialist and a Hematologist in Broomall, Pennsylvania. Dr. Sprandio is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Liver Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Sunita D. Nasta
Hematology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Sunita D. Nasta
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunita Nasta is a Hematologist in Philadelphia, Pennsylvania. Dr. Nasta is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Nasta is currently accepting new patients.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lai's expertise for a condition
ConditionClose
  • Elite
  • Acute Myeloid Leukemia (AML)
    Dr. Lai is
    Elite
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Distinguished
  • Leukemia
    Dr. Lai is
    Distinguished
    . Learn about Leukemia.
    See more Leukemia experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Lai is
    Distinguished
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Advanced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Lai is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Lai is
    Advanced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Lai is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Lai is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Promyelocytic Leukemia
    Dr. Lai is
    Advanced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adult T-Cell Leukemia
    Dr. Lai is
    Advanced
    . Learn about Adult T-Cell Leukemia.
    See more Adult T-Cell Leukemia experts
View All 20 Advanced Conditions
  • Experienced
  • Acute Myelomonocytic Leukemia
    Dr. Lai is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Anaplastic Large Cell Lymphoma
    Dr. Lai is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Anemia
    Dr. Lai is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Aplastic Anemia
    Dr. Lai is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • Burkitt Lymphoma
    Dr. Lai is
    Experienced
    . Learn about Burkitt Lymphoma.
    See more Burkitt Lymphoma experts
  • Chronic Familial Neutropenia
    Dr. Lai is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Close
      0 / 1000

      Please provide us with the below insurance information:

            By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.